2017 Perkin Medal – Ann E Weber, Ph.D.


AnneWeberDr. Weber’s research interests include the design and synthesis of ligands for G-protein coupled receptors, ion channels and enzymes.  Her work has led to over 40 development candidates, including JANUVIA® (sitagliptin), a treatment for patients with Type 2 diabetes (T2DM), JANUMET®, a fixed dose combination of sitagliptin and metformin, and MARIZEV® (omarigliptin), a once-weekly treatment for T2DM that was approved in Japan in September 2015.  An additional drug candidate, vibegron for the treatment of overactive bladder, is in late stage clinical trials.

Dr. Weber is the author or co-author of over 80 publications.  She is co-inventor on over 35 issued US patents.  Her awards include the Robert M. Scarborough Award for Excellence in Medicinal Chemistry (American Chemistry Society (ACS)), the Heroes of Chemistry Award (ACS), the Discoverer’s Award (PhRMA), recognizing scientists whose work has been of special benefit to humankind, and a Directors’ Award, the highest honor that Merck confers on its employees.  She is a 2013 Liberty Science Center Women in STEM Honoree and the recipient of the 2015 Gift of Mentoring Award from the Metro Women Chemists Committee.  In 2016 she was named to the Medicinal Chemistry Hall of Fame (ACS).

Before joining Merck, Dr. Weber obtained her B.S. degree in chemistry summa cum laude from the University of Notre Dame.  She earned her Ph.D. degree from Harvard University, studying synthetic organic chemistry in the laboratories of Professor David A. Evans.